Explore

Trendline Trendline
Seaport Therapeutics Reports Positive Phase 1 Trial Results for GlyphAgo in Anxiety Treatment

Seaport Therapeutics Reports Positive Phase 1 Trial Results for GlyphAgo in Anxiety Treatment

Seaport Therapeutics Reports Positive Phase 1 Trial Results for GlyphAgo in Anxiety Treatment
Trendline Trendline
Seaport Therapeutics Advances GlyphAgo with Positive Phase 1 Trial Results for Anxiety Treatment

Seaport Therapeutics Advances GlyphAgo with Positive Phase 1 Trial Results for Anxiety Treatment

Seaport Therapeutics Advances GlyphAgo with Positive Phase 1 Trial Results for Anxiety Treatment
Trendline Trendline
Seaport Therapeutics Reports Positive Phase 1 Data for GlyphAgo in Anxiety Disorder Treatment

Seaport Therapeutics Reports Positive Phase 1 Data for GlyphAgo in Anxiety Disorder Treatment

Seaport Therapeutics Reports Positive Phase 1 Data for GlyphAgo in Anxiety Disorder Treatment
Trendline Trendline
Seaport Therapeutics Announces Positive Phase 1 Trial Results for GlyphAgo in Anxiety Treatment

Seaport Therapeutics Announces Positive Phase 1 Trial Results for GlyphAgo in Anxiety Treatment

Seaport Therapeutics Announces Positive Phase 1 Trial Results for GlyphAgo in Anxiety Treatment
Trendline Trendline
Seaport Therapeutics Reports Financial Growth and Clinical Progress in Q1 2026

Seaport Therapeutics Reports Financial Growth and Clinical Progress in Q1 2026

Seaport Therapeutics Reports Financial Growth and Clinical Progress in Q1 2026
Trendline Trendline
Lifordi Immunotherapeutics Presents Promising Phase 1 Data for Rheumatoid Arthritis Treatment

Lifordi Immunotherapeutics Presents Promising Phase 1 Data for Rheumatoid Arthritis Treatment

Lifordi Immunotherapeutics Presents Promising Phase 1 Data for Rheumatoid Arthritis Treatment
Trendline Trendline
Verdiva Bio Unveils Promising Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions

Verdiva Bio Unveils Promising Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions

Verdiva Bio Unveils Promising Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions
Trendline Trendline
Kelun-Biotech and Windward Bio Initiate Phase 2 COPD Study for SKB378/WIN378

Kelun-Biotech and Windward Bio Initiate Phase 2 COPD Study for SKB378/WIN378

Kelun-Biotech and Windward Bio Initiate Phase 2 COPD Study for SKB378/WIN378
Trendline Trendline
Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA Combination

Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA Combination

Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA Combination
Trendline Trendline
Corsair Pharma Presents Phase 1 Data for TRX-248 Transdermal System at Pulmonary Hypertension Conference

Corsair Pharma Presents Phase 1 Data for TRX-248 Transdermal System at Pulmonary Hypertension Conference

Corsair Pharma Presents Phase 1 Data for TRX-248 Transdermal System at Pulmonary Hypertension Conference
Trendline Trendline
Lifordi Immunotherapeutics Unveils Promising Phase 1 Data for Rheumatoid Arthritis Treatment

Lifordi Immunotherapeutics Unveils Promising Phase 1 Data for Rheumatoid Arthritis Treatment

Lifordi Immunotherapeutics Unveils Promising Phase 1 Data for Rheumatoid Arthritis Treatment
Trendline Trendline
Bial's Phase 2b Study on Parkinson's Drug Fails to Meet Efficacy Endpoints

Bial's Phase 2b Study on Parkinson's Drug Fails to Meet Efficacy Endpoints

Bial's Phase 2b Study on Parkinson's Drug Fails to Meet Efficacy Endpoints